A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

Condition:   Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease Intervention:   Drug: macitentan 10 mg Sponsors:   Actelion;   Almac Clinical Technologies, LLC;   Frontier Science& Technology Research Foundation, Inc.;   Covance Central Laboratory Services, LP;   Chiltern International Ltd.;   WorldCare Clinical, LLC;   AcitGraph Corp.;   Medidata Solutions Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials